409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd
Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is
becoming an indispensable device for women to monitor their own biological rhythms.
Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services
as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO.
Would you like to be notified about new reports and other valuable content published by Venture Valuation?
Current transfusion medicine entirely relies on donated
blood. Megakaryon will change the transfusion practices by supplying
safe and cost-saving platelets produced in vitro. Mass production in
Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder.
Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO.
Inventiveness in peptide drug technology and a well thought-
out business strategy characterize PeptiDream’s thriving growth.
Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and
Chairman.
By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO
ObsEva is specialized in re energizing women’s reproductive and pregnancy therapeutics that have been overlooked and underserved for years. Venture Valuation (VV) interviewed Dr. Ernest Loumaye, co-founder and CEO.
Created by two scientists at the École
Politechnique Fédérale de Lausanne (EPFL) in 2014 and
joined by experienced drug development and business
professionals in 2015, Cellestia Biotech AG is developing
oral medication along with companion diagnostics for
Notch dependent hematological malignancies and solid tumors.
Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel, Switzerland.
<-- Interviews with leading Life Sciences companies: Oncolys BioPharma Inc. -->
Co-founded with Prof. Toshiyoshi Fujiwara1, the
inventor of the telomerase specific oncolytic adenovirus
technology, Oncolys BioPharma is committed to make its
therapeutic and diagnostic products available for patients with
intractable cancers.
Venture Valuation (VV) interviewed Yasunari Kashihara, Vice President, Business
Development, and Kohei Hata, Deputy Director, Corporate Development
Having leverage with its proprietary cell
sheet engineering platform technology1, Cellseed is going to
commercialize two products for which the regenerative
medicine market has hardly waited.
hardly waited for Venture Valuation (VV) interviewed the CEO, Dr. Setsuko Hashimoto